STOCK TITAN
  1. Home
  2. News
  3. HSDT

Helius Medical Technologies Inc - HSDT STOCK NEWS

Welcome to our dedicated news page for Helius Medical Technologies (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Medical Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Helius Medical Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Helius Medical Technologies's position in the market.

News
Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Helius Medical Technologies, Inc. (Nasdaq:HSDT) announces Q3 2023 results, with $143 thousand in revenue, a decrease from Q3 2022, and operating cash burn of $2.5 million. The company extended its cash runway into Q2 2024, and received UPC numbers for the PoNS system and mouthpiece, allowing for dual paths of reimbursement. A letter of intent from the Québec Ministry of Health and Social Services for the purchase of up to 30 PoNS systems was also received.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
earnings
-
News
Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work
Rhea-AI Summary
Helius Medical Technologies has announced the publication of a white paper demonstrating that rehabilitative treatment with the Portable Neuromodulation Stimulator (PoNS) can significantly improve return-to-work outcomes for patients suffering from traumatic brain injury (TBI). The study, co-sponsored by Pacific Blue Cross and HealthTech Connex, showed that 56% of participants who were previously unable to work due to TBI returned to their prior occupations after 14 weeks of PoNS Therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
-
News
Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024
Rhea-AI Summary
Helius Medical Technologies, Inc. expects to report Q3 revenues between $140,000 and $150,000 due to the conclusion of the Patient Therapy Access Program. They also anticipate having approximately $7.0 million in cash and extending their cash runway into Q2 2024. The company will release its Q3 2023 financial results on November 9, 2023, and will host a conference call to discuss the results and provide an update on their progress and plans for the U.S. commercialization of PoNS®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
earnings
News
Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices
Rhea-AI Summary
Helius Medical Technologies receives letter of intent from Québec Ministry of Health and Social Services for purchase of 30 PoNS devices
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
News
Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences
Rhea-AI Summary
Helius Medical Technologies CFO to participate in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
-
News
Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece
Rhea-AI Summary
Helius Medical Technologies has announced that its PoNS system and mouthpiece have been assigned UPC numbers by Wolters Kluwer Health, allowing the company to pursue reimbursement through both pharmacy and DME/HCPCS pathways. The PoNS system has a direct price of $25,700 and the mouthpiece has a direct price of $7,900. This development is seen as a gamechanger for Helius, potentially expediting negotiations with third-party payers and providing dual paths for potential reimbursement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
News
Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference
Rhea-AI Summary
Helius Medical Technologies will exhibit at the Academy of Neurologic Physical Therapy 2023 Annual Conference to showcase its Portable Neuromodulation Stimulator (PoNS®) therapy for people with multiple sclerosis (MS). The therapy, delivered through translingual neurostimulation, aims to improve gait deficit. The company's debut at the conference is timely, following National Rehabilitation Awareness Week and on the eve of National Physical Therapy Month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
-
News
University of Montreal’s School of Rehabilitation to Purchase Ten PoNS® Devices for Research Study on Stroke Recovery
Rhea-AI Summary
Helius Medical Technologies partners with Université de Montréal for stroke recovery study using PoNS Therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
News
Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference
Rhea-AI Summary
Helius Medical Technologies to present at IAFNR Conference on PoNS Therapy for balance and gait rehabilitation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
conferences
News
Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria
Rhea-AI Summary
Helius Medical Technologies, Inc. receives notice of compliance with Nasdaq bid price requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.5%
Tags
none
Stock HSDT logo
Helius Medical Technologies Inc

Nasdaq:HSDT

HSDT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

HSDT Stock Data

5.47M
829.47k
0.85%
11.59%
8.14%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
US
Newtown

About HSDT

helius medical technologies, inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. the company's product is portable neuromodulation stimulator (pons), a medical device in canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. its pons device treats neurostimulation of cranial nerves via the tongue to restore lost function. the company is headquartered in newtown, pennsylvania.